INS and Cognitive impairment: Furthermore, in either type 1 DM (T1D) or T2D subjects, treatment with insulin or insulin secretagogues can induce recurrent episodes of hypoglycemia, leading to brain neuronal dysfunction and increasing cognitive impairment and dementia development [35,36].